Literature DB >> 31161939

What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

Thomas R O'Brien1, Sarah S Jackson1.   

Abstract

Chronic infection with the hepatitis C virus (HCV) is a major cause of cirrhosis and hepatocellular carcinoma. In 2009, genome-wide association studies (GWAS) strongly linked genetic variants in the interferon lambda (IFN-λ) chromosomal region to HCV clearance. In 2013, discovery of the IFNL4 gene provided a functional explanation for those GWAS findings. The IFNL4-ΔG/TT (rs368234815) variant controls generation of the IFN-λ4 protein. Paradoxically, the IFNL4-TT allele, which abrogates IFN-λ4, associates with higher rates of spontaneous HCV clearance and better response to treatments for HCV infection. The finding that a "knock-out" allele for IFN-λ4 enhances HCV clearance challenges the paradigm of IFNs as antiviral cytokines. Genetic variants in the IFN-λ region have also been associated with hepatic inflammation and fibrosis from various etiologies, however, alleles that are linked with improved HCV clearance associates with worse inflammation and fibrosis. These studies demonstrate that GWAS of infectious diseases may yield important and unexpected biological insights.

Entities:  

Keywords:  IFNL4; epidemiology; fibrosis; genetics; hepatocellular carcinoma; innate immunity; treatment response; viral clearance

Mesh:

Substances:

Year:  2019        PMID: 31161939      PMCID: PMC6767860          DOI: 10.1089/jir.2019.0048

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  74 in total

Review 1.  Evolving epidemiology of hepatitis C virus.

Authors:  D Lavanchy
Journal:  Clin Microbiol Infect       Date:  2011-02       Impact factor: 8.067

2.  Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.

Authors:  Stéphanie Bibert; Agnieszka Wójtowicz; Patrick Taffé; Philip E Tarr; Enos Bernasconi; Hansjakob Furrer; Huldrych F Günthard; Matthias Hoffmann; Laurent Kaiser; Michael Osthoff; Jacques Fellay; Matthias Cavassini; Pierre-Yves Bochud
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

Review 3.  A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment.

Authors:  Julius Wilder; Anirudh Saraswathula; Vic Hasselblad; Andrew Muir
Journal:  J Natl Med Assoc       Date:  2016-02       Impact factor: 1.798

4.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity.

Authors:  Timothy J Nice; Megan T Baldridge; Broc T McCune; Jason M Norman; Helen M Lazear; Maxim Artyomov; Michael S Diamond; Herbert W Virgin
Journal:  Science       Date:  2014-11-27       Impact factor: 47.728

5.  IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.

Authors:  Sandra Franco; Ester Aparicio; Mariona Parera; Bonaventura Clotet; Cristina Tural; Miguel Angel Martinez
Journal:  AIDS       Date:  2014-01-02       Impact factor: 4.177

6.  Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.

Authors:  Salvatore Petta; Luca Valenti; Antonino Tuttolomondo; Paola Dongiovanni; Rosaria Maria Pipitone; Calogero Cammà; Daniela Cabibi; Vito Di Marco; Anna Ludovica Fracanzani; Sara Badiali; Valerio Nobili; Silvia Fargion; Stefania Grimaudo; Antonio Craxì
Journal:  Hepatology       Date:  2017-11-06       Impact factor: 17.425

7.  The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization.

Authors:  P P Anthony; K G Ishak; N C Nayak; H E Poulsen; P J Scheuer; L H Sobin
Journal:  J Clin Pathol       Date:  1978-05       Impact factor: 3.411

8.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors:  Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

9.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.

Authors:  Andri Rauch; Zoltán Kutalik; Patrick Descombes; Tao Cai; Julia Di Iulio; Tobias Mueller; Murielle Bochud; Manuel Battegay; Enos Bernasconi; Jan Borovicka; Sara Colombo; Andreas Cerny; Jean-François Dufour; Hansjakob Furrer; Huldrych F Günthard; Markus Heim; Bernard Hirschel; Raffaele Malinverni; Darius Moradpour; Beat Müllhaupt; Andrea Witteck; Jacques S Beckmann; Thomas Berg; Sven Bergmann; Francesco Negro; Amalio Telenti; Pierre-Yves Bochud
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

10.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Authors:  Mitchell L Shiffman; Fredy Suter; Bruce R Bacon; David Nelson; Hugh Harley; Ricard Solá; Stephen D Shafran; Karl Barange; Amy Lin; Ash Soman; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245

View more
  2 in total

1.  Functional genetic variants of the IFN-λ3 (IL28B) gene and transcription factor interactions on its promoter.

Authors:  Subhajit Roy; Debarati Guha Roy; Anand Bhushan; Seema Bharatiya; Sreedhar Chinnaswamy
Journal:  Cytokine       Date:  2021-03-13       Impact factor: 3.861

Review 2.  Occult Infection with Hepatitis C Virus: Looking for Clear-Cut Boundaries and Methodological Consensus.

Authors:  Anna Wróblewska; Krzysztof Piotr Bielawski; Katarzyna Sikorska
Journal:  J Clin Med       Date:  2021-12-14       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.